Estado del arte en primera línea de CPNM en pacientes sin mutaciones Driver Monoterapia vs combinación

13 / 54

Adverse Event
KEYNOTE 024
KEYNOTE 024
Update 2019
Pembro Chemo
Treatment related 73.4% 76.6% 90%
Grade ≥ 3 26.6% 31.2% 53.3%
Discontinuation 7.1% 13.6% 10.7%
Grade 5 <1% 1.3% 2%
Immune related
(All cause)
29.2% 33.8% 5.3%
Adverse Events
Reck M et al. NEJM: 375; 2016
Reck M et al. JCO 2019